Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters

This article was originally published in The Gold Sheet

Executive Summary

EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.

You may also be interested in...



J&J Building Electronic Drug-Tracking System In Anticipation of California’s E-Pedigree

House discussion draft of track-and-trace legislation draws fire from Democrats during April 25 hearings for failing to require a unit-level tracking system, but Energy and Commerce Committee Chairman plans markup of a bill in May and predicts a final measure will reach President Obama’s desk by the August recess.

Full Track-and-Trace Anti-Counterfeiting Not Feasible, Industry Tells FDA

The U.S. pharmaceutical industry is telling FDA that a full track-and-trace approach for following drugs through the supply chain is not the best way of dealing with the growing counterfeit problem. In the meantime, industry is devising a number of different approaches.

California E-Pedigree Law Pushes Final Implementation Back To 2016

California's latest electronic pedigree law pushes the deadline for all drugs sold in the state to carry track-and-trace information to 2016, a year later than an earlier version that was under consideration

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS000819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel